MicroRNA profiles of prostate cancer bone metastases and miR-375 as an inhibitor of the aggressive metastasis subtype MetB
Novel treatments for metastatic prostate cancer (PC) are needed. Molecular subtypes of bone metastatic PC (MetA-C) were recently identified, with the proliferation-driven MetB subtype linked to very poor prognosis. Non-coding microRNAs (miRs) regulate gene expression and constitute potential therapeutic targets. This s...